Filtering by: West Palm Beach

First Majestic Silver Corp. West Palm Beach Meeting (NYSE: AG)
Mar
1
12:00 PM12:00

First Majestic Silver Corp. West Palm Beach Meeting (NYSE: AG)

First Majestic (NYSE: AG) is a mining company focused on silver production in Mexico and is aggressively pursuing the development of its existing mineral property assets. The Company presently owns and operates six producing silver mines; the La Parrilla Silver Mine, the San Martin Silver Mine, the La Encantada Silver Mine, the La Guitarra Silver Mine, Del Toro Silver Mine and the Santa Elena Silver Mine . Production from these six mines is anticipated to be between 10.0 to 10.6 million ounces of pure silver or 15.7 to 16.6 million ounces of silver equivalents in 2017.

View Event →
Bio-Path Holdings (NASDAQ: BPTH) West Palm Beach Lunch
Nov
9
12:00 PM12:00

Bio-Path Holdings (NASDAQ: BPTH) West Palm Beach Lunch

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

  • Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
  • Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
  • Strong IP position with composition of matter and method patents for antisense targets and manufacturing
  • Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
  • Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment
View Event →